Business
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a comprehensive global intellectual property portfolio supporting vanoglipel (DA-1241), its novel, orally available G-protein-coupled receptor 119 (GPR119) agonist. This currently includes 48 granted and pending patents across three patent families in the U.S., Europe, Japan, China and other countries, providing protection into 2035, unless extended further.
About this update from Dong-a St Co., Ltd.
[{"type":"text","content":"Patent Portfolio Includes 48 Granted and Pending Patents in the U.S., Europe, Japan, China and other Countries, Providing Protection Into 2035, Unless Extended Further","length":167,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., March 12, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a comprehensive global intellectual property portfolio supporting vanoglipel (DA-1241), its novel, orally available G-protein-coupled receptor 119 (GPR119) agonist. This currently includes 48 granted and pending patents across three patent families in the U.S., Europe, Japan, China and other countries, providing protection into 2035, unless extended further.","length":543,"tagName":"p"},{"type":"image","alt":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","displaySize":"","headline":null,"caption":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":77,"url":"https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oKeVzvlzHhGood7_jpA63w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","width":400,"height":77}},"href":"https://mma.prnewswire.com/media/2568660/MetaVia_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"MetaVia's patent portfolio, exclusively licensed from Dong-A ST Co., Ltd., provides broad protection for vanoglipel itself, how it is manufactured, and its potential use across a range of serious metabolic and liver conditions. Collectively, the patents cover both the core compound and pharmaceutical compositions designed to treat diseases linked to metabolic dysfunction, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and diabetes.","length":458,"tagName":"p"},{"type":"text","content":""Maintaining and expanding a strong intellectual property position is a core element of our strategy to maximize the long-term value potential of vanoglipel," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "These patents reflect the broad therapeutic opportunity for DA-1241 across liver and metabolic diseases and reinforce our...